IPCA Laboratories

IPCA Laboratories P/B

The P/B (Price-to-Book Ratio) of IPCA Laboratories (IPCALAB.NS) as of Oct 28, 2026 is 4.72. In the previous year, P/B (Price-to-Book Ratio) was 5.48 — a change of -13.83% (lower).

P/B

4.72

YoY

-13.83%

Last updated:

P/B (Price-to-Book Ratio) of IPCA Laboratories is 2026 4.72 . P/B (Price-to-Book Ratio) of IPCA Laboratories was 2025 5.48 . It decreases by -13.83% lower compared to the previous year.

The IPCA Laboratories P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
12.19 INR
Jan 1, 2020
10.49 INR
Jan 1, 2021
8.09 INR
Jan 1, 2022
6.96 INR
Jan 1, 2023
6.51 INR
Jan 1, 2024
6.01 INR
Jan 1, 2025
5.48 INR
Jan 1, 2026
4.72 INR
The IPCA Laboratories P/B history
YEARP/BYoY
4.72-13.83%
5.48-8.87%
6.01-7.74%
6.51-6.46%
6.96-13.97%
8.09-22.85%
10.49-13.92%
12.19-13.89%
14.15-8.68%
15.50-7.99%
16.84-2.25%
17.23-11.26%
19.42—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

P/B (Price-to-Book Ratio) of IPCA Laboratories is 4.72 in 2026.

P/B (Price-to-Book Ratio) of IPCA Laboratories changed from 5.48 to 4.72, representing a -13.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s IPCA Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — IPCA Laboratories

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — IPCA Laboratories